Abstract Background/Aims: Non-small cell lung carcinoma (NSCLC) metastasis to bone leads to skeletal-related events and a poor quality of life. Unravelling the mechanism of metastasis is crucial for improving survival. Previous work has implicated the role of CXCR4 in bone metastasis; however, the underlying mechanisms are unknown. Methods: The human bone metastasis tissue samples were obtained from lung cancer patients during surgery with consents. The patients were followed up and the overall survival curve was analysed. The expression of CXCR4, VCAM1, and ADAM17 was measured with real-time PCR, western blot and immunochemistry staining in human tissue or NSCLC cell lines. The effects of CXCR4, soluble VCAM1 and ADAM17 on NSCLC proliferation, migration and invasion were measured with CCK-8, monolayer scratch assay and transwell chamber, respectively. The amount of soluble VCAM1 in the conditioned medium was detected with ELISA. Tartrate-resistant acid phosphatasethe (TRAP) staining was performed to stain the multinucleated cells regarded as osteoclasts. Results: In this study, CXCR4 was found to be highly expressed in bone destruction area of metastatic NSCLC samples and related to poor survival in NSCLC patients with bone metastasis. CXCR4 potentiated NSCLC with enhanced proliferation and invasion abilities, while CXCR4 knockdown significantly suppressed the growth and invasion. Furthermore, CXCR4 promoted lung cancer-induced osteoclast differentiation with increased osteoclast formation. We also found that soluble VCAM1 (sVCAM1) secreted in NSCLC contributed to the osteoclastogenesis induced by CXCR4. The overexpression of CXCR4 increased sVCAM1, and the sVCAM1 secreted from CXCR4-overexpressing NSCLC cells recruited and arrested additional osteoclast progenitors to promote osteoclastogenesis. ADAM17 was confirmed to act as a 
Introduction
Lung cancer is the leading malignancy worldwide in men and the second-leading malignancy in women [1, 2] . Primary lung cancer includes small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC), and the latter accounts for 85% of all lung cancer cases [3] . NSCLC frequently metastasizes to bone, which is often associated with skeletalrelated events (SREs), defined as pathologic fracture, spinal cord compression, bone pain and hypercalcaemia [4] . However, the underlying mechanisms of the metastatic capacity of NSCLC remain elusive.
CXCR4, a chemokine receptor, and its sole agonist CXCL12 have been reported to play an essential role in multiple solid tumours, including prostate [5] , brain, breast [6] , colon [7] and lung cancers [8, 9] . There is growing evidence suggesting that the CXCL12/CXCR4 axis is important for tumour-related mechanisms such as chemotaxis, invasion, tumorigenicity, angiogenesis and proliferation. Higher levels of CXCR4 are associated with poor prognosis and a high risk of SRE development, which inversely correlates with quality of life and survival time in affected patients [10, 11] . Metastasis to the bone and the consequent SREs processes through metastatic quiescence, formation of tumour cell niches and, finally, tumour cell growth. During cancer-induced bone destruction, extensive studies have demonstrated that osteoclast differentiation is a key process in cancer-associated bone resorption. CXCL12/ CXCR4 contributes to certain tumour-mediated metastasis [12, 13] ; however, the role and mechanism of CXCR4 in the osteoclastogenesis of NSCLC metastasis to the bone remains largely unknown.
Metastatic bone lesions arise due to the intricate interaction between tumour cells and the bone microenvironment [14] . Tumour cells, osteoblasts, osteoclasts, bone extracellular matrix, the bone microenvironment and the niche are major components of a vicious cycle necessary for the initiation and development of metastatic lesions in the skeleton. The osteoclastogenic factors produced by localized tumour cells converge to increase the expression of the receptor activator of NF-κB ligand (RNAKL). RANKL then binds to the RANK receptor on osteoclast precursors and mediates osteoclastogenesis. Upon activation of RANKL and its receptor, CXCL12/CXCR4 efficiently potentiates the formation of osteoclasts and resorption by RAW264.7 cells [15] . Tumour-released osteoclastogenic factors that are regulated by CXCR4 may be of great value as therapeutic targets.
VCAM1 belongs to a transmembrane immunoglobulin family and is mainly expressed in stimulated endothelial cells [16] . VCAM1 can be catalysed to soluble VCAM1 (sVCAM1). The major receptor of VCAM1 is α4β1 (very late antigen-4, VLA-4), which is expressed in many haematopoietic cells, including lymphocytes, monocytes and granulocytes. In breast cancer, VCAM1 was shown to be involved in the micro-environmental interaction between tumour cells and stromal cells and facilitate the metastasis of breast cancer cells to the bone [17] . Additionally, the serum VCAM1 levels in NSCLC patients are significantly higher compared with those in healthy subjects. However, whether CXCR4 regulates VCAM1 during the bone metastasis of NSCLC remains unknown.
Soluble forms of adhesion molecules such as VCAM1 are thought to be a result of proteolytic cleavage. The disinterring metalloproteinases (ADAMs) have been shown to be involved in the majority of protein shedding. Previous studies have shown that ADAM17 is responsible for the shedding of numerous receptors for oncogenic growth factors, cytokines and adhesion molecules, including VCAM1 [18] . Meanwhile, aberrant ADAM17 expression is related to aggressive lung cancer and poor prognosis [19] . Recently, it was reported that Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry the incubation was continued for an additional 2 h. The absorbance value (OD) was measured at 450 nm using a microplate reader (Varioskan Flash, Thermo Scientific, USA).
Invasion and migration assays
The invasion assay was performed using Transwell invasion chambers (Corning, NY, USA). H1299 and H1975 cells were plated in the top chamber in medium without serum and treated with 20 ng/mL of recombinant human CXCL12. Medium containing 10% FBS was added to the bottom chamber. After 24 h, the cells were fixed and stained with 0.1% crystal violet. Cells invading through the membrane were counted using a light microscope. For the migration assay, H1299 and H1975 cells were seeded in 12-well plates in medium containing 0.1% FBS. The wound was created by scratching with a 100-μl pipette tip, and the cells were treated with 20 ng/mL of recombinant human CXCL12 in 10% FBS RPMI 1640 to stimulate cell migration. Images of wound healing were captured at 0, 24 and 48 h.
ELISA detection
The concentration of sVCAM1 was estimated using ELISA kits (BD Biosciences, USA). After treatment, the cell supernatants were isolated by centrifugation, and VCAM1 expression was detected according to the manufacturer's instructions. The absorbance was read at 450 nm using a microplate reader (Thermo Fisher, USA).
Real-time PCR
At the indicated time, total RNA was extracted from cells using TRIzol reagent (Invitrogen, USA). Firststrand complementary DNA was reversed from 1 mg of total RNA using the Primer Script RT Reagent Kit (TaKaRa, Dalian, China). Quantitative real-time PCR was performed using a SYBR Green Premix Ex Taq Kit on a 7500 FAST LightCycler (ABI, USA) according to the manufacturer's protocol. The sequences of the primers used for real-time PCR are shown in Table 1 . The relative expression of mRNA was normalized to GAPDH.
Western blot
The cells were lysed with RIPA buffer containing protease inhibitors (Beyotime, China). Proteins from the cell lysates were quantified using the BCA method, separated on an SDS-PAGE gel and transferred onto PVDF membranes. Next, the membranes were blocked and incubated with a specific primary antibody. The primary antibodies were used at the following dilutions: anti-CXCR4 (1:1000); anti-ADAM17 (1:1000); and anti-VCAM1 (1:500). After being washed, the membranes were incubated with an HRP-linked secondary antibody. The immunoreactive bands were detected using the Chemiluminescent HRP Substrate (Millipore, USA). GAPDH was re-probed to serve as a control.
TRAP staining
Tartrate-resistant acid phosphatasethe (TRAP) staining was performed with TRAP kits (Sigma, St. Louis, MO, USA). The 4-μm-thick slices were incubated in the fixation solution for 30 seconds and transferred to the TRAP solution for 60 min at 37 °C. The nuclei were visualized with haematoxylin staining. For the in vitro osteoclastogenesis assay, RAW264.7 cells were plated in 24-well plates incubated with 10 ng/mL RNAKL or combined with other treatments for 5 days. TRAP staining was applied according to the manufacturer's instructions. The stained sections and cells were viewed with an electron microscope (Olympus BX63, Tokyo, Japan). TRAP-positive multinucleated cells containing more than 3 nuclei were regarded as osteoclasts.
Immunohistochemistry staining
Immunohistochemistry was performed using the Polink-1 one-step polymer detection system (ZSGB-BIO, China). Following deparaffinisation and rehydration, the sections were microwaved in 0.01 mol/L sodium citrate (80 °C for 50 min, followed by 40 °C for 10 min) and incubated with anti-α-SMA antibody primary antibodies (CXCR4, 1:50; VCAM1, 1:100; ADAM17, 1:50) overnight at 4 °C. After incubation with a one-step polymer secondary antibody at room temperature for 50 min, the signal was visualized using diaminobenzidine (DAB). Images were captured using an Olympus microscope (Tokyo, Japan).
Statistics
The data are presented as the mean ± SEM. The Kaplan-Meier method and log-rank test were applied for survival time. The student's t-test or Mann-Whitney U test was used for comparison between two groups. Statistical significance was determined by one-way ANOVA among three group' comparisons, using SPSS 16.0 software (SPSS, Chicago, IL, USA); p<0.05 was considered significant.
Results

CXCR4 is related to osteoclastogenesis in human metastatic bone tissue in NSCLC
To investigate the role of CXCR4 expressed by NSCLC cell lines in the development of bone metastasis, we first detected CXCR4 expression in NSCLC human tissues. In the bone destruction area, CXCR4 is aberrantly expressed (Fig. 1A) . Further, the osteoclastogenesis response in the bone destruction area on the consecutive slices, as evaluated using TRAP staining, was related to CXCR4 expression, as shown in Fig. 1A . The number of TRAP-positive multinucleated cells was considerably higher on the surface with high CXCR4 expression (Fig.  1A) . Among the NSCLC bone metastasis patients undergoing surgery, 32 were followed up. Kaplan-Meier survival analysis implied that patients with high expression of CXCR4 seemed to suffer lower overall survival time rate as shown in Fig. 1B , consistent with previous clinical reports [21, 22] . A log-rank test further confirmed that a significant difference between overall survival time. Kaplan-Meier survival analysis of overall survival in all patients with NSCLC bone metastasis was generated according to CXCR4 protein expression. The expression of CXCR4 was determined by immunostaining in samples from 31 NSCLC patients. Patients were divided into high CXCR4 expression group (n =23) (score ++ and +++) and low CXCR4 expression group (n=8) (score+ and −). The overall survival was compared between low and high CXCR4 expression groups. The log-rank test was applied to calculate p value. 
CXCR4 knockdown inhibits NSCLC invasion, migration and proliferation in vitro
To investigate the role of NSCLC CXCR4 in the development of bone metastasis, we first screened CXCR4 expression in several NSCLC cell lines, including A549, H1975 and H1299. Among them, the evaluation of both mRNA levels and protein expression showed that the CXCR4 expression was the highest in the H1299 cell line, while it was the lowest in the H1975 cells ( Fig. 2A ). Based on this result, we further evaluated CXCR4 in these cell lines to determine its effects on bone metastasis.
To determine the role of CXCR4 in NSCLC potentiation, three siRNA vectors were constructed and transfected into H1299 cells, in which CXCR4 was demonstrated to be relatively highly expressed (Fig. 2B ). As shown in Fig. 3A , two of the siRNA against CXCR4, namely, si-CXCR4a and si-CXCR4b, showed high knockdown efficiency, while si-CXCR4c exhibited minimal effects. Consistently, si-CXCR4a effectively downregulated the CXCR4 protein expression (Fig. 3B ) and, thus, was chosen for further studies.
Given the pivotal role of migration and invasion in cancer bone metastasis, we further determined the effects of CXCR4 knockdown in H1299 cells on invasive ability. As shown in Fig. 3C&D , the wounded-monolayer assay showed that at both 24 h and 48 h, siRNA against CXCR4 remarkably suppressed H1299 cell migration. Meanwhile, H1299 cells were seeded in the upper Transwell chamber and stimulated with serum to migrate into the bottom chamber. The cells that migrated into the lower membrane were counted. The results showed that the number of migrated cells in the CXCR4-knockdown group was significantly reduced compared with that in either the scrambled siRNA group or the control group (Fig.  3E ). Additionally, we measured H1299 cell proliferation upon stimulation with CXCL12. In the CXCR4-knockdown group, the absorbance values were decreased at both 48 h and 72 h under stimulation with CXCL12 compared with that in the scrambled group. Taken together, these results indicated that knocking down CXCR4 in NSCLC could block the migratory, invasive and proliferative ability that vitally contribute to bone metastasis.
CXCR4 overexpression accelerates NSCLC invasion, migration and proliferation in vitro
In H1975 cells with relatively low CXCR4 expression, we overexpressed CXCR4 via an adenovirus to determine its effects on bone metastasis. We first confirmed the efficiency of the adenovirus transfection into the H1975 cells, and the mRNA levels were markedly increased, as shown in Fig. 4A . Correspondingly, the protein levels were increased to 2.38-fold compared with the negative control group (Fig. 4B ). In the wound-healing experiment, the healing distance was substantially greater in the CXCR4-overexpression group compared with the control group (Fig. 4C&D) . Likewise, the Transwell invasion assay showed that the migrated cells in the CXCR4-overexpression group were markedly increased compared with those in the control group (Fig. 4E) . Moreover, the H1975 cells transfected with the CXCR4-carrying adenovirus exhibited a remarkable increase in proliferation ability at both 48 h and 72 h compared with the control group (Fig. 4F) . Therefore, these data indicated that CXCR4 overexpression potentiates NSCLC growth and invasion. 
Role of CXCR4 in lung cancer-induced osteoclast differentiation and function
The receptor activator of nuclear factor-κB ligand (RANKL) could induce the formation of TRAP-positive multinucleated osteoclasts. Conditioned medium harvested from H1299 cells transfected with the negative control siRNA significantly promoted the differentiation of osteoclasts, as shown in Fig. 5A&B . Conditioned medium from CXCR4-knockdown cells images were recorded at 0, 24 and 48 h post-wound time points. D. Quantification of healing distance (n=3, *p<0.05, compared with the control group or siRNA negative control group). E. Matrigel assay of H1299 cells transfected with siRNA against CXCR4 or control siRNA. Migratory cells were counted in 10 non-overlapping areas and quantified using a bar graph (n=3, *p<0.05, compared with the control group or siRNA negative control group). F. H1299 cell proliferation was measured using a CCK-8 kit. The OD values were measured at 24, 48 and 72 h in the control group and CXCR4-knockdown group (n=5, *p<0.05, compared with the siRNA negative control group). showed a decrease in TRAP-positive osteoclasts compared with that from the negative control group (Fig. 5A) . Further, we measured the mRNA levels of TRAP and cathepsin K, which are markers of osteoclasts. Both TRAP and cathepsin K mRNA levels were increased in the presence of conditioned medium upon stimulation with RANKL (Fig. 5C) . However, the increase in the TRAP and cathepsin K mRNA were blunted in the presence of the conditioned medium from the CXCR4-knockdown NSCLC cells (Fig. 5C) . p<0.01 compared with the negative control adenovirus transfection group). G. TRAP staining was performed to detect RAW264.7 cell differentiation following treatment with 10 ng/mL RNAKL and culture medium from CXCR4-overexpressing H1975 cells in the presence or absence of 10 ng/ml AMD3100, as indicated. H. Quantification of TRAP-positive cells upon stimulation with culture media from CXCR4-overexpressing H1975 cells in the presence or absence of AMD3100 (n=3, *p<0.05). I. mRNA levels of osteoclast differentiation marker genes cathepsin K and TRAP in treated RAW264.7 cells were measured via RT-PCR at 48 h in the indicated groups (n=3, *p<0.05). 
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On the other hand, we investigated the effects of conditioned medium from the CXCR4-overexpressing H1975 cells on osteoclast differentiation. The conditioned medium from the CXCR4-overexpressing NSCLC cells dramatically stimulated osteoclast differentiation (Fig.  5D&E) . Similarly, the mRNA levels of TRAP and cathepsin K were upregulated in the group treated with the conditioned medium from the CXCR4-overexpressing NSCLC cells compared with that in the vector group (Fig. 5F ).
AMD3100, a well-recognized CXCR4 antagonist, was further employed to determine the effects of CXCR4 inhibition on osteoclast differentiation. The conditioned medium harvested from the CXCR4-overexpressing NSCLC cells with the addition of AMD3100 showed less multinucleated osteoclasts stained with TRAP (Fig. 5G&H) . Likewise, the mRNA levels of TRAP and cathepsin K in the RAW264.7 cells were decreased upon stimulation with conditioned medium from the CXCR4-overexpression group in the presence of AMD3100 compared with that in the corresponding control group (Fig. 5I) . J. CXCR4, VCAM1, and ADAM17 expression in human specimens on consecutive slices with immunohistochemistry. 
VCAM1 is involved in the CXCR4-positive-NSCLC-induced osteoclast activation
We first measured VCAM1 expression in different NSCLC cell lines. Consistent with CXCR4 expression, the mRNA levels of VCAM1 in the H1299 cells are higher than those in the H1975 cell lines, as shown in Fig. 6A . Aberrant CXCR4 overexpression induced significant VCAM1 expression in H1975 cells (Fig. 6B) , while CXCR4 downregulation decreased VCAM1 expression in H1299 cells (Fig. 6C) . In the CXCR4-overexpression group, sVCAM1 levels in the culture medium were increased compared with those in the control group (Fig. 6D) . The CXCR4 inhibitor AMD3100 decreased the secretion of sVCAM1 to the medium, which was enhanced by CXCR4 overexpression in the presence of CXCL12 (Fig. 6D) . In the NSCLC cells, the increase in the VCAM1 mRNA induced by CXCR4 overexpression was blunted by AMD3100 (Fig. 6D&E) . Moreover, VCAM1 might interact with its receptor α4β1 on preosteoclasts to promote osteoclastogenesis [17] . We mimicked that scenario by precoating the wells with VCAM1-rich conditioned medium from CXCR4-overexpressing NSCLC cells before seeding RAW264.7 cells. The coating with the VCAM1-rich conditioned medium resulted in earlier multi-nucleation and more TRAP+ osteoclasts (Fig. 6F) . On the other hand, supplementation with a VCAM1 antibody blocked the maturation of the RAW264.7 cells seeded in the VCAM1-coated conditioned medium and reduced the multinucleated TRAP+ osteoclasts (Fig. 6G) . Taken together, these results indicated that the sVCAM1 secreted from the CXCR4-overexpressing NSCLC cells may recruit and arrest more osteoclast progenitors to promote osteoclastogenesis.
ADAM17 might mediate VCAM1 secretion in CXCR4-overexpressing NSCLC tumour cells and participate in CXCR4-accelerated osteoclastogenesis
Previously, it has been reported that ADAM17 is involved in VCAM1 cleavage and facilitates the secretion of sVCAM1 [18] . We determined whether ADAM17 acts as a downstream regulator of CXCR4. ADAM17 was detected in different NSCLC cell lines with varying CXCR4 expression. We observed that ADAM17 has a similar expression profile as CXCR4 (Fig. 7A&B) . CXCR4 overexpression led to the upregulation of ADAM17 (Fig. 7C) . In the presence of the ADAM17 inhibitor TAPI-2, the ADAM17 expression induced by CXCR4 was decreased compared with that in the control group (Fig. 7D) . Further, the suppression of ADAM17 decreased the number of TRAP+ osteoclasts (Fig. 7E &F) . The osteoclast marker genes TRAP and CK were also inhibited in the presence of TAPI-2 (Fig. 7G) .
Meanwhile, CXCR4 overexpression via adenovirus upregulated the VCAM1 expression in NSCLC cells, as described above (Fig. 6B) . We further observed that inhibition of ADAM17 via TAPI-2 attenuated the elevation of VCAM1 induced by CXCR4 at both mRNA levels and the soluble form in NSCLC cells (Fig. 7H&I) . Likewise, the sVCAM1 in the conditioned medium was significantly lower in the presence of TAPI-2 (Fig. 7H) . Therefore, we could infer that ADAM17 functions as a downstream moderator during CXCR4-accelerated osteoclastogenesis and that ADAM17 plays a vital role in the release of sVCAM1 into the cell medium, which acts on osteoclast progenitors and, eventually, leads to activation of osteoclastogenesis.
We recapitulated our observation in the human samples. Consecutive slices immunostaining showed that higher CXCR4 expression in the NSCLC metastatic bone tissues correlate with aberrant expression of VCAM1, and ADAM17 compared with CXCR4 low expression group (Fig. 7J ). This observation in human samples further supported the mechanisms that ADAM17 might participate in the regulation of VCAM1 by CXCR4 during NSCLC metastasis to bone.
Discussion
NSCLC remains a life-threatening disease, and its metastasis to bone accelerates disease progression. To develop targeted therapeutic modalities, it is important to delineate the mechanism underlying the bone metastasis of NSCLC. In this report, we confirmed the differential expression of CXCR4 in different NSCLC cell lines and the distribution of CXCR4 Tumour cells disseminate from the tumour mass and metastasize to distant tissues. The bone has physical properties that sustain tumour cell proliferation and provide a large surface, a hypoxic environment and growth factors. Approximately 36% of patients with multiple skeleton-favouring tumours present with bone lesions at autopsy [23] . The median survival time from the diagnosis of advanced lung cancer is usually counted in months [23] . Despite the short survival time, SREs developed at a high rate. Moreover, some NSCLC patients are diagnosed because of pain and SREs. The progression to SREs leads to a reduction in quality of life and a poor prognosis. Therefore, studying the mechanisms accounting for the bone metastasis of NSCLC is of great importance to improve the outcome of lung cancer patients.
Increasing studies have shown that CXCR4 is significantly elevated in a wide range of tumours, such as lung cancer and gastric cancer [24, 25] . Not limited to the in-site tumours, aberrant CXCR4 overexpression was detected in circulating tumour cells and tumour metastasis target organs, including lung, brain, bone and liver. Clinically, a growing body of evidence has shown that CXCR4 predicts poor prognosis of patients with lung cancer [26] . A meta-analysis indicated that CXCR4 expression is associated with an increased risk and worse survival in NSCLC patients [27] .
CXCR4 is a chemokine receptor expressed by NSCLC that can bind to factors produced by the bone and bone marrow, such as stromal derived factor-1 (SDF1). Tumour cells achieve local reabsorption through the osteoclastogenesis process. During osteoclastogenesis, tumour cells activate osteoclast precursor cells of the monocyte/macrophage cell line and stimulate their fusion and formation of mature osteoclasts. Among multiple osteoclastogenesis signalling pathways, the RNAKL/RANK/osteoprotegerin system is the most recognized axis. In this study, we observed that CXCR4 expression was considerably different among various NSCLC cell lines and human samples. The differences were tightly related to clinical outcomes. Our finding was consistent with other clinical investigations [26, 28, 29] . Liu et al. reported that NSCLC with CXCR4 expression has a higher odds ratio with late-stage lung cancer, lymph node involvement and bone metastasis [26] . We found that CXCR4 exhibited a significant positive correlation with overall survival time. Furthermore, we demonstrated that the poor outcome could be explained by the potentiation of NSCLC through the aberrant expression of CXCR4. CXCR4-positive tumours exhibited accelerated proliferation and invasion ability. Hence, CXCR4 might serve as a prognostic factor for lung cancer patient survival and might be an emerging therapeutic target.
VCAM1 is a well-known cell surface immunoglobulin molecule. It has been reported to be constitutively expressed on several different cells, including endothelial cells, stromal cells and many tumour cells. VCAM1 mediates cell adhesion physically and, thus, appears to be of special interest for its pivotal role in the process of tumour invasion and metastatic spread. According to previously published literature, sVCAM1 levels are elevated in patients with lung cancer [30, 31] , breast cancer and even colorectal carcinomas compared with control subjects [32] [33] [34] . In this study, we confirmed that in human metastatic samples from bone, VCAM1 was upregulated on the tumour-bone surface in the bone destruction area. Consistently, we further discovered that sVCAM1 was increased in the conditioned medium from the CXCR4-overexpressing NSCLC cells and that it promoted osteoclastogenesis through interaction with osteoclast progenitors. This result supported an observation in breast-cancer-induced metastasis. In breast cancer bone metastasis, VCAM1 was indicated to promote osteolytic expansion through binding to its cognate α4β1 receptor in osteoclast progenitors [17] . Therefore, we speculated that the interaction between VCAM1 and α4β1 might contribute to increased osteoclastogenesis in NSCLC. Moreover, increased expression of CXCR4 and VLA-4 integrin resulted in concentration-dependent chemotaxis to their ligands, CXCL12 and VCAM-1 in T cells [35] . The cross talk between CXCL12/CXCR4 and VLA-4/VCAM-1 was further validated in the bone marrow [36] . Previously reports also showed that in astrocytes CXCL12 stimulation could induce the NF κB activation and TNF α release [37] , concomitantly the transcription regulation between NF κB and VCAM1 has been well established. Hence, we reasoned that NF κB might be one of the possible mechanisms CXCR4 regulates VCAM1. However, further investigation is still needed. ADAM17 belongs to the disintegrin and metalloprotease gene family [38] , and it has been reported to be upregulated in NSCLC and other tumour entities. Aberrant ADAM17 expression was associated with a poor survival time [39] . ADAM17 can be activated by radiotherapy in NSCLC, which results in shedding of multiple survival factors and growth factor pathway activation [40] . A previous study showed that ADAM17 downregulation suppresses NSCLC migration and invasion [38] . Our results extend this observation; we found that ADAM17 was regulated by CXCR4. Meanwhile, our results indicated that ADAM17 inhibition inactivated osteoclastogenesis. In murine endothelial cells, ADAM17 was reported to serve as the protease responsible for shedding of endogenous VCAM1 and sVCAM1 release [18] . Therefore, we reasoned that VCAM1 might contribute to ADAM17-mediated osteoclastogenesis. ADAM17 inhibition decreased NSCLC VCAM1 expression and led to a reduction of sVCAM1 in the conditioned medium. In summary, we innovatively established a cross talk between the CXCL12/CXCR4 axis and the ADAM17/VCAM1 interaction.
The limitations of this study should be taken into consideration. First, our findings need to be further evaluated using in vivo animal models. In vivo tumour models could be more convincing to demonstrate the role of CXCR4 in tumorigenesis and bone metastasis. Second, we performed studies on human samples and follow-up studies in patients with NSCLC. However, a prospective cohort study might illustrate the predictive value of CXCR4 and sVCAM1 for prognosis. Finally, it would be valuable to determine the concrete function of VCAM1 during osteoclastogenesis.
Conclusion
We determined the important role of CXCR4 in NSCLC-induced bone metastasis. CXCR4 appears to potentiate the outgrowth of NSCLC, promote the invasion ability of NSCLC, and enhance osteoclastogenesis through sVCAM1. Further, we confirmed that ADAM17 is involved in sVCAM1 cleavage and participates in NSCLC-mediated osteoclastogenesis. The cross talk between CXCR4 signalling and the ADAM17 cleavage of VCAM1 were established in this study. These data may indicate the potential therapeutic value of the CXCR4-ADAM17-VCAM1 axis.
